IM Cannabis (IMCC) Competitors $2.07 -0.11 (-5.00%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$2.18 +0.11 (+5.50%) As of 02/21/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IMCC vs. GELS, LPCN, APRE, LPTX, MIRA, OKUR, COCP, NNVC, GLYC, and MRKRShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Gelteq (GELS), Lipocine (LPCN), Aprea Therapeutics (APRE), Leap Therapeutics (LPTX), MIRA Pharmaceuticals (MIRA), OnKure Therapeutics (OKUR), Cocrystal Pharma (COCP), NanoViricides (NNVC), GlycoMimetics (GLYC), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Gelteq Lipocine Aprea Therapeutics Leap Therapeutics MIRA Pharmaceuticals OnKure Therapeutics Cocrystal Pharma NanoViricides GlycoMimetics Marker Therapeutics Gelteq (NASDAQ:GELS) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Which has higher earnings & valuation, GELS or IMCC? Gelteq has higher earnings, but lower revenue than IM Cannabis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteqN/AN/AN/AN/AN/AIM Cannabis$36.15M0.13-$7.04M-$3.41-0.61 Is GELS or IMCC more profitable? Gelteq has a net margin of 0.00% compared to IM Cannabis' net margin of -25.55%. Gelteq's return on equity of 0.00% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A IM Cannabis -25.55%-129.86%-23.63% Do institutionals & insiders have more ownership in GELS or IMCC? 7.7% of IM Cannabis shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer GELS or IMCC? In the previous week, Gelteq's average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score. Company Overall Sentiment Gelteq Neutral IM Cannabis Neutral Does the MarketBeat Community prefer GELS or IMCC? IM Cannabis received 6 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformGelteqN/AN/AIM CannabisOutperform Votes642.86% Underperform Votes857.14% SummaryIM Cannabis beats Gelteq on 4 of the 7 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.87M$1.16B$5.84B$9.14BDividend YieldN/AN/A4.75%3.85%P/E Ratio-0.6135.7826.0419.11Price / Sales0.135.72447.4676.36Price / CashN/A10.4038.0134.83Price / Book0.461.927.644.62Net Income-$7.04M-$53.22M$3.18B$245.85M7 Day Performance-7.96%-5.53%-2.00%-2.61%1 Month Performance-11.50%-1.92%-0.44%-2.14%1 Year Performance4.19%-13.79%16.44%12.98% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis0.4468 of 5 stars$2.07-5.0%N/A-6.7%$4.87M$36.15M-0.61340Gap DownGELSGelteqN/A$2.11-4.5%N/AN/A$19.92MN/A0.00N/AGap UpLPCNLipocine1.6881 of 5 stars$3.63+2.5%$10.00+175.5%-14.4%$19.42M$500,000.00-4.7810Analyst ForecastGap DownAPREAprea Therapeutics2.1246 of 5 stars$3.58+1.3%$15.50+333.6%-58.3%$19.41M$580,000.00-1.277LPTXLeap Therapeutics1.3579 of 5 stars$0.50-0.8%$4.92+876.1%-84.0%$19.30MN/A-0.2640MIRAMIRA Pharmaceuticals2.1128 of 5 stars$1.16-2.5%$14.00+1,106.9%+1.9%$19.21MN/A-2.072OKUROnKure Therapeutics2.6327 of 5 stars$5.74+2.0%$36.00+527.2%N/A$19.17MN/A-0.47N/AGap UpCOCPCocrystal Pharma2.6063 of 5 stars$1.87+0.5%$7.00+274.3%+32.7%$19.02MN/A-1.0110NNVCNanoViricidesN/A$1.35+4.7%N/A+21.0%$18.83MN/A-1.7820Gap UpGLYCGlycoMimetics4.1636 of 5 stars$0.29+2.2%$8.00+2,658.6%-90.1%$18.70M$10,000.000.0050Analyst ForecastNews CoverageGap DownHigh Trading VolumeMRKRMarker Therapeutics4.3474 of 5 stars$1.72+1.2%$19.00+1,004.7%-59.9%$18.42M$3.31M0.0060 Related Companies and Tools Related Companies GELS Competitors LPCN Competitors APRE Competitors LPTX Competitors MIRA Competitors OKUR Competitors COCP Competitors NNVC Competitors GLYC Competitors MRKR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMCC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
